Skip to content
TrialScanner

NCT05233033

Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL

Phase 1CompletedKYMRLead

Registry record

Lead sponsor
Kymera Therapeutics, Inc.
Conditions
Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; DLBCL; MYD88 Gene Mutation
Primary completion
Jul 28, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05233033 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.